[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
July 11, 2007

Novel Therapies Target Myasthenia Gravis

JAMA. 2007;298(2):163-164. doi:10.1001/jama.298.2.163

Chicago—Advances in the treatment of myasthenia gravis have come a long way and mortality from the disease now occurs in less than 5% of affected individuals. But current therapies are nonspecific and can cause a variety of adverse effects and health risks.

Researchers are hopeful that improved therapies could battle the disease more effectively and provide patients with a better quality of life. Scientists pursuing research that might lead to new treatment options for patients with this rare chronic autoimmune neuromuscular disorder met here recently at the International Conference on Myasthenia Gravis and Related Disorders to discuss promising new findings.